258 related articles for article (PubMed ID: 26433844)
1. The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma.
Huen AO; Kim EJ
Dermatol Clin; 2015 Oct; 33(4):715-29. PubMed ID: 26433844
[TBL] [Abstract][Full Text] [Related]
2. [Thyroid and lipidic dysfunction associated with bexarotene in cutaneous T-cell lymphoma].
Rodriguez Suarez S; Pamies Andreu E; Muñiz Grijalvo O; Garcia Morillo JS
Med Clin (Barc); 2016 Feb; 146(3):117-20. PubMed ID: 26688184
[TBL] [Abstract][Full Text] [Related]
3. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
Sokolowska-Wojdylo M; Florek A; Zaucha JM; Chmielowska E; Giza A; Knopinska-Posluszny W; Kulikowski W; Prejzner W; Romejko-Jarosinska J; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Rogowski W; Grzanka A; Placek W; Lugowska-Umer H; Kowalczyk A; Nowicki R; Jurczak W
Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
[TBL] [Abstract][Full Text] [Related]
4. Combination of retinoids and PUVA (Re-PUVA) in the treatment of cutaneous T cell lymphomas.
Serri F; De Simone C; Venier A; Rusciani L; Marchetti F
Curr Probl Dermatol; 1990; 19():252-7. PubMed ID: 2404681
[No Abstract] [Full Text] [Related]
5. The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma.
Spaccarelli N; Rook AH
Dermatol Clin; 2015 Oct; 33(4):731-45. PubMed ID: 26433845
[TBL] [Abstract][Full Text] [Related]
6. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
[TBL] [Abstract][Full Text] [Related]
7. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
8. Skin-Directed Therapies in Cutaneous T-Cell Lymphoma.
Nguyen CV; Bohjanen KA
Dermatol Clin; 2015 Oct; 33(4):683-96. PubMed ID: 26433841
[TBL] [Abstract][Full Text] [Related]
9. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
10. State of the art therapy of mycosis fungoides and Sézary syndrome.
Kemme DJ; Bunn PA
Oncology (Williston Park); 1992 Feb; 6(2):31-42; discussion 44, 47-8. PubMed ID: 1532501
[TBL] [Abstract][Full Text] [Related]
11. Pentostatin plus cyclophosphamide and bexarotene is an effective and safe combination in patients with mycosis fungoides/Sezary syndrome.
Calderon Cabrera C; de la Cruz Vicente F; Marín-Niebla A; Carrillo Cruz E; Rios Herranz E; Espigado Tocino I; Prats Martín C; Falantes JF; Martino Galiana ML; Perez-Simón JA
Br J Haematol; 2013 Jul; 162(1):130-2. PubMed ID: 23581433
[No Abstract] [Full Text] [Related]
12. Endocrine side-effects of anti-cancer drugs: the impact of retinoids on the thyroid axis.
Graeppi-Dulac J; Vlaeminck-Guillem V; Perier-Muzet M; Dalle S; Orgiazzi J
Eur J Endocrinol; 2014 Jun; 170(6):R253-62. PubMed ID: 24616413
[TBL] [Abstract][Full Text] [Related]
13. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
Duvic M
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):33-40. PubMed ID: 17474358
[TBL] [Abstract][Full Text] [Related]
14. Bexarotene and systemic disease progression in CTCL?
Dummer R; Hauschild A; Skalsky J; Burg G; Weichenthal M
J Am Acad Dermatol; 2006 Aug; 55(2):365-6; author reply 366. PubMed ID: 16844539
[No Abstract] [Full Text] [Related]
15. Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
Stern DK; Lebwohl M
J Drugs Dermatol; 2002 Sep; 1(2):134-6. PubMed ID: 12847736
[TBL] [Abstract][Full Text] [Related]
16. Treatment of cutaneous T-cell lymphoma with the arotinoid Ro 13-6298.
Tousignant J; Raymond GP; Light MJ
J Am Acad Dermatol; 1987 Jan; 16(1 Pt 2):167-71. PubMed ID: 3493269
[TBL] [Abstract][Full Text] [Related]
17. [Bexarotene therapy in folliculotropic cutaneous T-cell lymphoma].
Drugeon C; Charlat I; Boulinguez S; Viraben R
Ann Dermatol Venereol; 2007; 134(8-9):639-43. PubMed ID: 17925686
[TBL] [Abstract][Full Text] [Related]
18. Sézary syndrome in an 11-year-old girl.
Meister L; Duarte AM; Davis J; Perez JL; Schachner LA
J Am Acad Dermatol; 1993 Jan; 28(1):93-5. PubMed ID: 8425978
[TBL] [Abstract][Full Text] [Related]
19. Topical and systemic retinoid therapy for cutaneous T-cell lymphoma.
Kempf W; Kettelhack N; Duvic M; Burg G
Hematol Oncol Clin North Am; 2003 Dec; 17(6):1405-19. PubMed ID: 14710892
[TBL] [Abstract][Full Text] [Related]
20. CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature.
Gopaluni S; Perzova R; Abbott L; Farah R; Shrimpton A; Hutchison R; Poiesz BJ
Am J Hematol; 2008 Sep; 83(9):744-6. PubMed ID: 18615708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]